TNGX
Tango Therapeutics, Inc.
Next earnings Aug 3, 2026 · consensus $-0.33 EPS
Last earnings +8.6% on 2026-05-13
$29.46
▼ -9.52%$29.46▲ +488.02%
over 1Y
L $5.01H $32.90
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-9.5%
1W-2.3%
1M+37.0%
3M+36.2%
YTD+229.9%
1Y+488.0%
Avoid
Conviction
Horizon
Long (>12mo)
Street · 18 analysts
Buy
Pre-product precision-oncology biotech burning ~$139M/yr at 64x sales — binary clinical risk, not investable on fundamentals.
P/S 64.0 · FY2025
Tango Therapeutics is a clinical-stage precision-oncology company with, in its own words, a limited operating history, no products approved for commercial sale, and no revenue from product sales. The $62.4M of FY2025 revenue (+48.3%) is collaboration income, not drug sales, and the company has never successfully completed any clinical trials. The financials reflect a pre-commercial biotech: operating loss of -$111M, net loss of -$102M (diluted EPS -$0.87), and an accumulated deficit (retained earnings) of -$603M. Operating margin is -178.4% and return on equity -29.3%.
The valuation is the disqualifier. At $27.97 the market cap is $3.99B, a stunning 64.0x sales for a company with no approved products and a -162.9% net margin. The P/E is meaningless (negative). The stock fell 13.38% today, underscoring how violently the price reacts to news in a name where value is entirely tied to unproven, binary clinical readouts. There is no earnings or cash-flow anchor to fall back on.
Is TNGX a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread (caution)~90d expiry
- Long put 29 @ ~8.12 est
- Short put 27 @ ~6.90 est
debit $122max +$78max −$122BE 27.78
AVOID means we wouldn't engage at all — if expressing the short side anyway, only with capped risk.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $37.0M | $24.9M | $36.5M | $42.1M | $62.4M |
| Gross profit | — | — | — | — | — |
| Operating income | -$58.2M | -$111M | -$114M | -$146M | -$111M |
| Net income | -$58.2M | -$108M | -$102M | -$130M | -$102M |
| Diluted EPS | -$0.94 | -$1.23 | -$1.08 | -$1.19 | -$0.87 |
| Net margin | -157.2% | -435.1% | -278.5% | -309.7% | -162.9% |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$4.68B
EV / EBITDA—
EV / Sales75.1
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-2.1%
FCF yield-2.9%
Quality & risk
ROIC (est.)-25.4%
Free cash flow-$140M
Total debt—
Net cash$112M
Altman Z-Score52.92 safe
Piotroski F-Score3/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+32.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Officer / director change2026-06-23
- 8-K Material agreement2026-06-10
- 8-K Reg FD disclosure2026-06-08
- 8-K Shareholder vote2026-06-04
- 8-K Officer / director change2026-05-13
- 10-Q Quarterly report2026-05-13
- 8-K Officer / director change2026-05-08
- DEF 14A Proxy statement2026-04-17
- 10-K Annual report2026-03-05
Recent filings
all on EDGAR ↗4Period ending 2026-07-012026-07-02open ↗4Period ending 2026-06-192026-06-23open ↗3Period ending 2026-06-192026-06-23open ↗8-KPeriod ending 2026-06-192026-06-23open ↗144Filing2026-06-17open ↗144Filing2026-06-11open ↗8-KPeriod ending 2026-06-092026-06-10open ↗424B5Filing2026-06-10open ↗144Filing2026-06-10open ↗FWPFiling2026-06-10open ↗4Period ending 2026-06-052026-06-08open ↗4Period ending 2026-06-052026-06-08open ↗
Frequently asked
- Is Tango Therapeutics, Inc. (TNGX) a buy?
- TNGX currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Pre-product precision-oncology biotech burning ~$139M/yr at 64x sales — binary clinical risk, not investable on fundamentals.
- What is Tango Therapeutics, Inc.'s quality score?
- TNGX scores 51.8069783520821/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001819133, latest 10-Q filed 2026-05-13) · EODHD · Proprietary analysis · as of 6/21/2026, 8:47:55 PM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:47 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.